{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T16:23:46Z","timestamp":1781886226446,"version":"3.54.5"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T00:00:00Z","timestamp":1692144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Objective:<\/jats:bold> To investigate the clinical efficacy and toxicity of nebulized polymyxin monotherapy and combined intravenous and nebulized polymyxin for the treatment of VAP caused by CR-GNB. Additionally, among patients treated with nebulized polymyxin monotherapy, we compared the clinical efficacy and toxicity of polymyxin B and polymyxin E.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> This study was a single-center, retrospective study. Included patients received aerosolized polymyxin for at least 72\u00a0h with or without intravenous polymyxin for the management of CR-GNB VAP. The primary endpoint was clinical cure at the end of polymyxin therapy. Secondary endpoints included AKI incidence, time of bacteria-negative conversion, duration of MV after inclusion, length of stay in ICU, and all-cause ICU mortality.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> 39 patients treated with nebulized polymyxin monotherapy were assigned to the NL-polymyxin group. 39 patients treated with nebulized polymyxin combined with intravenous use of polymyxin were assigned to the IV-NL-polymyxin group. Among the NL-polymyxin group, 19 patients were treated with polymyxin B and 20 with polymyxin E. The clinical baseline characteristics before admission to the ICU and before nebulization of polymyxin were similar between the two groups. No differences were found between the two study groups in terms of microorganism distribution, VAP cure rate, time of bacteria-negative conversion, duration of MV after inclusion, length of stay in ICU and all-cause ICU mortality. Similarly, survival analysis did not differ between the two groups (\u03c7<jats:sup>2<\/jats:sup> = 3.539, <jats:italic>p<\/jats:italic> = 0.06). AKI incidence was higher in the IV-NL-polymyxin group. When comparing the clinical efficacy and toxicity to polymyxin B and polymyxin E, there was no difference between the two groups in terms of VAP cure rate, time of bacteria-negative conversion, duration of MV after inclusion, length of stay in ICU, SOFA score, CPIS, AKI incidence and all-cause ICU mortality.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Our study found that nebulized polymyxin monotherapy was non-inferior to combination therapy with intravenous polymyxin in treating CR-GNB-VAP. Furthermore, we observed no differences in clinical efficacy or related toxic side effects between polymyxin B and polymyxin E during nebulized polymyxin therapy as monotherapy. However, future prospective studies with larger sample sizes are required to confirm these findings.<\/jats:p>","DOI":"10.3389\/fphar.2023.1209063","type":"journal-article","created":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T07:53:14Z","timestamp":1692345194000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Comparison of the clinical efficacy and toxicity of nebulized polymyxin monotherapy and combined intravenous and nebulized polymyxin for the treatment of ventilator-associated pneumonia caused by carbapenem-resistant gram-negative bacteria: a retrospective cohort study"],"prefix":"10.3389","volume":"14","author":[{"given":"Zhenping","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yelin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyuan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,8,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13613-016-0127-7","article-title":"Efficacy and toxicity of aerosolised colistin in ventilator-associated pneumonia: a prospective, randomised trial","volume":"6","author":"Abdellatif","year":"2016","journal-title":"Ann. Intensive Care"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.3760\/cma.j.issn.2095-4352.2019.10.003","article-title":"Chinese expert consensus on polymyxins in the clinical practice","volume":"31","author":"Chinese","year":"2019","journal-title":"Zhonghua Wei Zhong Bing Ji Jiu Yi Xue"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1753466619885529","DOI":"10.1177\/1753466619885529","article-title":"Inhalation with intravenous loading dose of colistin in critically ill patients with pneumonia caused by carbapenem-resistant gram-negative bacteria","volume":"13","author":"Choe","year":"2019","journal-title":"Ther. Adv. Respir. Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1038\/s41564-019-0492-8","article-title":"Epidemic of carbapenem-resistant Klebsiella pneumoniae in Europe is driven by nosocomial spread","volume":"4","author":"David","year":"2019","journal-title":"Nat. Microbiol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1152\/physiolgenomics.00076.2013","article-title":"Cell cycle arrest in a model of colistin nephrotoxicity","volume":"45","author":"Eadon","year":"2013","journal-title":"Physiol. Genomics"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1007\/s00134-020-06036-z","article-title":"Diagnosis of ventilator-associated pneumonia in critically ill adult patients-a systematic review and meta-analysis","volume":"46","author":"Fernando","year":"2020","journal-title":"Intensive Care Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"28","DOI":"10.2478\/jccm-2020-0044","article-title":"The susceptibility of MDR-K. Pneumoniae to polymyxin B plus its nebulised form versus polymyxin B alone in critically ill south asian patients","volume":"7","author":"Hasan","year":"2021","journal-title":"J. Crit. Care Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"S128","DOI":"10.1093\/cid\/ciy657","article-title":"Current status and trends of antibacterial resistance in China","volume":"67","author":"Hu","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of America and the American thoracic society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1002\/ppul.22750","article-title":"Colistin inhalation monotherapy for ventilator-associated pneumonia of Acinetobacter baumannii in prematurity","volume":"49","author":"Kang","year":"2014","journal-title":"Pediatr. Pulmonol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1183\/13993003.02235-2014","article-title":"Nebulised colistin for ventilator-associated pneumonia prevention","volume":"46","author":"Karvouniaris","year":"2015","journal-title":"Eur. Resp. J."},{"key":"B12","doi-asserted-by":"publisher","first-page":"c179","DOI":"10.1159\/000339789","article-title":"KDIGO clinical practice guidelines for acute kidney injury","volume":"120","author":"Khwaja","year":"2012","journal-title":"Nephron"},{"key":"B13","doi-asserted-by":"publisher","first-page":"555","DOI":"10.21037\/jtd.2017.02.61","article-title":"Efficacy of nebulized colistin-based therapy without concurrent intravenous colistin for ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii","volume":"9","author":"Kim","year":"2017","journal-title":"J. Thorac. Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"5244538","DOI":"10.1155\/2022\/5244538","article-title":"Effects of aerosol inhalation combined with intravenous drip of polymyxin B on bacterial clearance, symptoms improvement, and serum infection indexes in patients with pneumonia induced by multidrug-resistant gram-negative bacteria","volume":"2022","author":"Lin","year":"2022","journal-title":"Emerg. Med. Int."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e00211","DOI":"10.1128\/AAC.00211-17","article-title":"Aerosolized polymyxin B for treatment of respiratory tract infections: determination of pharmacokinetic-pharmacodynamic indices for aerosolized polymyxin B against Pseudomonas aeruginosa in a mouse lung infection model","volume":"61","author":"Lin","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B16","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/s0140-6736(85)92222-6","article-title":"Nebulised colomycin for early pseudomonas colonisation in cystic fibrosis","volume":"1","author":"Littlewood","year":"1985","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/ALN.0b013e31827515de","article-title":"Efficacy of high-dose nebulized colistin in ventilator-associated pneumonia caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii","volume":"117","author":"Lu","year":"2012","journal-title":"Anesthesiology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"R78","DOI":"10.1186\/cc2358","article-title":"Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients","volume":"7","author":"Markou","year":"2003","journal-title":"Crit. Care"},{"key":"B19","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.cmi.2017.04.011","article-title":"Use of nebulized antimicrobials for the treatment of respiratory infections in invasively mechanically ventilated adults: a position paper from the European society of clinical microbiology and infectious diseases","volume":"23","author":"Rello","year":"2017","journal-title":"Clin. Microbiol. Infect."},{"key":"B20","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/BF01704698","article-title":"Prevention of gram negative nosocomial bronchopneumonia by intratracheal colistin in critically ill patients. Histologic and bacteriologic study","volume":"20","author":"Rouby","year":"1994","journal-title":"Intensive Care Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1700582","DOI":"10.1183\/13993003.00582-2017","article-title":"International ERS\/ESICM\/ESCMID\/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: guidelines for the management of hospital-acquired pneumonia (HAP)\/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociacion Latinoamericana del Torax (ALAT)","volume":"50","author":"Torres","year":"2017","journal-title":"Eur. Resp. J."},{"key":"B22","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/phar.2209","article-title":"International consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of clinical pharmacy (ACCP), European society of clinical microbiology and infectious diseases (ESCMID), infectious diseases society of America (IDSA), international society for anti-infective Pharmacology (ISAP), society of critical care medicine (SCCM), and society of infectious diseases pharmacists (SIDP)","volume":"39","author":"Tsuji","year":"2019","journal-title":"Pharmacotherapy"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijantimicag.2017.05.016","article-title":"Inhaled colistin monotherapy for respiratory tract infections in adults without cystic fibrosis: a systematic review and meta-analysis","volume":"51","author":"Vardakas","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1021\/jm900999h","article-title":"Structure--activity relationships of polymyxin antibiotics","volume":"53","author":"Velkov","year":"2010","journal-title":"J. Med. Chem."},{"key":"B25","doi-asserted-by":"publisher","first-page":"023199","DOI":"10.1128\/AAC.02319-16","article-title":"Nephrotoxicity of polymyxins: is there any difference between colistimethate and polymyxin B? Antimicrob","volume":"61","author":"Zavascki","year":"2017","journal-title":"Agents Chemother."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s12325-020-01235-y","article-title":"Effectiveness and safety of high dose tigecycline for the treatment of severe infections: a systematic review and meta-analysis","volume":"37","author":"Zha","year":"2020","journal-title":"Adv. Ther."},{"key":"B27","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.jmii.2019.08.007","article-title":"Colistin for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex","volume":"53","author":"Zheng","year":"2020","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"B28","doi-asserted-by":"publisher","first-page":"416","DOI":"10.3760\/cma.j.cn121430-20201215-00753","article-title":"Clinical study on intravenous combined with aerosol inhalation of polymyxin B for the treatment of pneumonia caused by multidrug-resistant Gram-negative bacteria","volume":"33","author":"Zhou","year":"2021","journal-title":"Zhonghua Wei Zhong Bing Ji Jiu Yi Xue"},{"key":"B29","doi-asserted-by":"publisher","first-page":"S131","DOI":"10.1086\/653062","article-title":"Ventilator-associated pneumonia: the clinical pulmonary infection score as a surrogate for diagnostics and outcome","volume":"51","author":"Zilberberg","year":"2010","journal-title":"Clin. Infect. Dis."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1209063\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T07:53:20Z","timestamp":1692345200000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1209063\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,16]]},"references-count":29,"alternative-id":["10.3389\/fphar.2023.1209063"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1209063","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,16]]},"article-number":"1209063"}}